Why Regeneron Pharmaceuticals, Inc. (REGN) Stock Rose 13.3% on Oct 30, 2026
What happened
Regeneron reported third-quarter 2026 earnings and revenues that beat analyst estimates (Globe Newswire, Zacks), driving a sharp rally of +11.91% to $916.31. The beat follows recent analyst upgrades ahead of the report (Benzinga).
Next earnings release scheduled for 2027-01-29; consensus EPS estimate $20.87. Monitor for any analyst rating or price-target changes in the coming days following this beat.
Other developments that session
Regeneron Pharmaceuticals, Inc. (REGN) reported EPS of $20.07 vs. consensus estimate of $16.42, beating by 22.2%.
Regeneron Pharmaceuticals, Inc. (REGN) filed a new 10-Q on October 30, 2026, covering its most recent quarter.
Regeneron reported Q3 EPS of $20.07, exceeding consensus estimate of $16.08 by 25%.
Frequently asked questions
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock rise on Oct 30, 2026?
Regeneron reported third-quarter 2026 earnings and revenues that beat analyst estimates (Globe Newswire, Zacks), driving a sharp rally of +11.91% to $916.31. The beat follows recent analyst upgrades ahead of the report (Benzinga).
How much did REGN stock rise on Oct 30, 2026?
REGN rose 13.3% during the Oct 30, 2026 trading session.